COVID-related mucormycosis mimicking dental infection

A recent increase in the prevalence of mucormycosis of the head and neck in patients who have recovered from COVID-19 following hospitalization has been reported. A Majority of the cases have been reported from India. Conditions such as diabetes mellitus, use of corticosteroids for other autoimmune conditions, organ transplant, immunosuppression, immunodeficiency, and malignancies especially hematologic ones, are all known risk factors for mucormycosis. Recently, hospitalization for COVID-19 has been added to the list of risk factors for opportunistic mucormycosis infection. This is likely attributable to the high doses and prolonged use of corticosteroids in the treatment of hospitalized COVID-19 patients. Case Description: Two patients with post-COVID-19 associated rhinocerebral mucormycosis presented with profound unexplained dental disease including tooth mobility and dental abscess mimicking periodontal disease. The patients were previously hospitalized for COVID-19 and received prolonged treatment with high doses of corticosteroids. The patients responded well to the surgical debridement with or without antifungal therapy. Conclusion: Oral healthcare providers including oral and maxillofacial surgeons, dentists, dental hygienists, and other dental practitioners can play a vital role in the recognition and early diagnosis of rhinocerebral mucormycosis given the large number of patients with severe COVID-19 infection who have recovered following hospitalization and/or received long-term high doses of immunosuppressive treatment. •Oral and maxillofacial surgeons can play a vital role in the recognition and early diagnosis of rhinocerebral mucormycosis.•Aggressive systemic steroid therapy in hospitalized COVID-19 patients especially those with diabetes is associated with an increased risk of rhinocerebral mucormycosis.•Rhinocerebral mucormycosis may present clinically as an aggressive periodontal disease with teeth mobility.•Early medical intervention is paramount to disease-free survival with minimal tissue destruction/loss.•Written consents were obtained from patients. Copies are available upon request.